Randomised trial of effects of interferon-?? on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis

Nishiguchi, Shuhei; Kuroki, T; Nakatani, Shinji; Morimoto, Hideki; Takeda, Tadashi; Nakajima, Shinya; Shiomi, Susumu; Seki, Satoko; Kobayashi, Koju; Otani, Satoshi

doi:10.1097/00042737-199512000-00023

Cited by 289 publications

(453 citation statements)

References 0 publications

Supporting

Mentioning

423

Contrasting

Unclassified

Order By: Relevance

“…Tumor volumes ranged 0.9 to 6.4 ϫ 10 3 mm. 3 The volume of liver tumors did not differ significantly between mice that had received inoculations and those that had not. However, inoculated mice had no liver tumors Ͻ300 mm, 3 whereas 56.3% (9/16) of liver tumors were of this size in uninoculated mice.…”

Section: Effect Of Inoculation With Dc/mih-2 On Tumor Volumementioning

confidence: 86%

“…2 Treatment with IFN-␣ decreases the incidence of HCC in patients with chronic hepatitis C with or without cirrhosis, especially in biologic or virologic responders. [3][4][5][6] Once HCC has developed, possible treatments include surgical resection, transcatheter arterial embolization and radiofrequency, ethanol, and microwave ablation. [7][8][9] However, the high rate of recurrence, which may be due to intrahepatic metastases and multicentric development, is an important clinical problem.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice

Irie

Homma

Komita

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

Section: Effect Of Inoculation With Dc/mih-2 On Tumor Volumementioning

confidence: 86%

mentioning

confidence: 99%

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice

Irie

Homma

Komita

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

“…13 However, IFN was reported to prevent the development of HCC even in patients in whom the therapy was not effective. 16 Further follow-up studies of IFN-treated patients are essential given that the incidence of HCC in patients with chronic HCV infection increases with its progress over the time of follow-up.…”

Section: Discussionmentioning

confidence: 99%

Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C

Hamada

Yatsuhashi

Yano

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDHepatitis C virus (HCV) infection is a heterogeneous disease, the natural history of which remains controversial. There is solid evidence that chronic HCV infection is responsible for the occurrence of hepatocellular carcinoma (HCC). The aim of the current cohort study was to determine the rate of the development of HCC from the time of primary HCV infection and to assess the risk factors for the development of HCC in chronic posttransfusion hepatitis C patients.METHODSFour hundred sixty‐nine patients with clinically compensated HCV, who had undergone a single blood transfusion comprised the current study cohort. Patients with other risk factors for chronic liver disease were excluded. All patients were referred to the liver center at the National Nagasaki Medical Center between December 1980 and December 1998 and were followed prospectively until the end of the analysis (June 2000).RESULTSFollow‐up data were obtained for 445 patients. The mean duration from HCV infection to the end of the observation was 28 years. Fifty‐two patients (11.1%) progressed to HCC. The mean duration from the time of blood transfusion to the diagnosis of HCC was 31 years. Multivariate Cox regression analyses revealed age, fibrosis, duration from HCV infection to study entry, and alcohol consumption to be the independent factors affecting the development of HCC. The risk of developing HCC in patients age ≥ 56 years was increased 7.8‐fold compared with that in patients age < 56 years. The mean age of patients at the time of HCC diagnosis was 65 years (range, 58–79 years).CONCLUSIONSAt the time of diagnosis, 92% of the 52 HCC patients were age > 60 years and 38 of the HCC patients (73%) were in their 60s. There was a significantly negative correlation between the duration from HCV infection to the development of HCC and the age of the patient at the time of infection (correlation coefficient = 0.702; P < 0.0001; Y = 61.1–0.82X), indicating that the age of patients, rather than the duration of HCV infection, is more significant for HCC development in patients with posttransfusion HCV. Moreover, these data may contribute to the design of an optimal follow‐up schedule for patients with posttransfusion HCV. Cancer 2002;95:331–9. © 2002 American Cancer Society.DOI 10.1002/cncr.10662

show abstract

“…Therefore, it is very important to prevent recurrence. Recent studies have shown that IFN therapy is associated with reducing the incidence of HCCin patients with chronic hepatitis C and type C cirrhosis (3,4). Wehave also reported previously the results of a case showing the effect of IFNtherapy in preventing HCCrecurrence (5).…”

Section: Discussionmentioning

confidence: 84%

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Kudo

Terao

Arita³

et al. 2002

Intern. Med.

View full text Add to dashboard Cite

A complete response was obtained by interferon (IFN) therapy for hepatitis C virus (HCV)-related advanced chronic hepatitis after curative treatment of initial and recurrent hepatocellular carcinoma (HCC). The patient is alive 73 months after diagnosis of initial HCCand is in a tumor-free state 53 months after diagnosis of the last HCC. This case suggest that it is possible to suppress recurrence and to prolong the life of patients with HCV-related advanced chronic hepatitis, if a complete response is obtained by means of IFN therapy after the curative treatment of the recurrent HCC. (Internal Medicine 41 : 202-206, 2002)

show abstract

Randomised trial of effects of interferon-?? on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis

Cited by 289 publications

References 0 publications

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice

Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C

Interferon Therapy for Hapatitis C Virus (HCV)-related Advanced Chronic Hepatitis after Treatment of Recurrent Hepatocellular Carcinoma: A Successful Case.

Contact Info

Product

Resources

About